| For: | Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol 2018; 10(11): 790-794 [PMID: 30533179 DOI: 10.4254/wjh.v10.i11.790] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v10/i11/790.htm |
| Number | Citing Articles |
| 1 |
Maria-Styliani Kalogirou, Dimitrios Patoulias, Anna-Bettina Haidich, Evangelos Akriviadis, Emmanouil Sinakos. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2021; 45(3) doi: 10.1016/j.clinre.2020.10.012
|
| 2 |
Hae Jin Kim. Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist. The Journal of Korean Diabetes 2021; 22(2) doi: 10.4093/jkd.2021.22.2.126
|
| 3 |
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. Metabolism 2019; 101 doi: 10.1016/j.metabol.2019.154001
|
| 4 |
Jingya Lyu, Hitomi Imachi, Kensaku Fukunaga, Seisuke Sato, Toshihiro Kobayashi, Tao Dong, Takanobu Saheki, Mari Matsumoto, Hisakazu Iwama, Huanxiang Zhang, Koji Murao. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. Molecular Metabolism 2020; 34 doi: 10.1016/j.molmet.2019.12.015
|
| 5 |
Alexander Myint. Improvement of liver function and glycemic control with Combination of DPP-4 inhibitors and GLP-1 agonists in type II diabetes mellitus patients with non-alcoholic steatohepatitis. Gastroenterology & Hepatology: Open Access 2020; 11(3) doi: 10.15406/ghoa.2020.11.00427
|
| 6 |
Parth Shah, Megan White, Alex Sievert, Alexander Conway, Adam Kneepkens, Gregory Sayuk, Mauricio Lisker‐Melman, Jill Elwing. Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study. JGH Open 2024; 8(2) doi: 10.1002/jgh3.13037
|
| 7 |
Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants 2022; 11(6) doi: 10.3390/antiox11061060
|
| 8 |
Mohamed Elnaggar, Omar F. Abbas, Abdullah Almarfadi, Abdelrahman Refaei, Hatem Eltaly, Mohamed Abd El Aziz. Efficacy of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Current Hepatology Reports 2026; 25(1) doi: 10.1007/s11901-025-00718-2
|
| 9 |
Maja Cigrovski Berkovic, Lucija Virovic-Jukic, Ines Bilic-Curcic, Anna Mrzljak. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World Journal of Gastroenterology 2020; 26(21): 2740-2757 doi: 10.3748/wjg.v26.i21.2740
|
| 10 |
Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacological Research 2020; 159 doi: 10.1016/j.phrs.2020.104984
|
| 11 |
Seol Hwa Seo, Eunhwan Kim, Minguen Yoon, Soung-Hoon Lee, Byung-Hyun Park, Kang-Yell Choi. Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment. Experimental & Molecular Medicine 2022; 54(9) doi: 10.1038/s12276-022-00851-8
|
| 12 |
Donna Lee, Joel Zonszein. A Case-Based Guide to Clinical Endocrinology. 2022; doi: 10.1007/978-3-030-84367-0_40
|
| 13 |
Ja Young Jeon, Hae Jin Kim. Stroke Revisited: Diabetes in Stroke. Stroke Revisited 2021; doi: 10.1007/978-981-16-5123-6_14
|
| 14 |
Timothy Koch, David Cronin, Ali Iranmanesh. The Prevalence of Steatohepatitis Declines with Age in Non-urban Individuals with Obesity. International Journal of Gastroenterology 2026; 10(1) doi: 10.11648/j.ijg.20261001.16
|
| 15 |
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.609110
|
| 16 |
E. S. Shcherbakova, T. S. Sall, S. I. Sitkin, T. Ya. Vakhitov, E. V. Demyanova. The role of bacterial metabolites derived from aromatic amino acids in non-alcoholic fatty liver disease. Almanac of Clinical Medicine 2020; 48(6) doi: 10.18786/2072-0505-2020-48-066
|
| 17 |
Chun-Chi Yang, Jheng-Yan Wu, Ya-Yun Cheng, Hsuan-Yuan Chang, Su-Hung Wang, I-Che Feng, Hsing-Tao Kuo, Ming-Lung Yu, Wei-Ting Chang. Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence. Diabetes Research and Clinical Practice 2026; 235 doi: 10.1016/j.diabres.2026.113206
|
| 18 |
ARKA DE AJAY DUSEJA. Future pharmacotherapy for non-alcoholic steatohepatitis. The National Medical Journal of India 2022; 34 doi: 10.25259/NMJI_103_21
|
| 19 |
Joeri Lambrecht, Leo A. van Grunsven, Frank Tacke. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opinion on Pharmacotherapy 2020; 21(13) doi: 10.1080/14656566.2020.1774553
|
| 20 |
Ruben Vazquez-Uribe, Karl Alex Hedin, Tine Rask Licht, Max Nieuwdorp, Morten O.A. Sommer. Advanced microbiome therapeutics as a novel modality for oral delivery of peptides to manage metabolic diseases. Trends in Endocrinology & Metabolism 2025; 36(1) doi: 10.1016/j.tem.2024.04.021
|
| 21 |
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa M. Sahoo. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharmaceutical Research 2022; 39(6) doi: 10.1007/s11095-022-03302-1
|
| 22 |
Yunzhi Chen, Xuemei Yan, Xiao Xu, Shuhua Yuan, Fen Xu, Hua Liang. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide. Endocrine 2020; 70(3) doi: 10.1007/s12020-020-02470-7
|